The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...

(Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® (maralixibat) for the treatment of cholestatic pruritus in ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food ...

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

In the gastric environment the surface of the tablet transforms into a gel through ... This new tramadol once-daily (OAD) formulation was created with the aim of providing continuous drug delivery ...

Conclusions: In accordance with previous results, this study confirmed the pharmacokinetic differences between a standard ibuprofen tablet formulation and fast-dissolving formulations. Ibuprofen ...

Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...